Manuel Sánchez-Solís de Querol, Silvia Gartner, Vicente María Bosch Giménez, L. García Marcos
Background Infections by respiratory syncytial virus (RSV) are more severe in patients with cystic fibrosis (CF), and many CF units use palivizumab as prophylaxis; however, information about palivizumab efficacy in CF patients is almost lacking.
Methods A literature search up to December 2012 on the morbidity of RSV bronchiolitis in CF patients and on the safety and efficacy of palivizumab in those patients was performed. A random-effects meta-analysis was conducted for those studies meeting pre-specified search criteria. Historical controls were allowed.
Results The number of patients who received palivizumab was 354 and the hospital admission rate was 0.018 (95% CI 0.0077–0.048). The corresponding number in the non-treated groups was 463 patients with an admission rate of 0.126 (95% CI 0.086–0.182) (Q = 13.9; p < 0.001).
Conclusion Palivizumab may have a role in the prevention of severe lower airway infection by RSV in CF patients.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados